Galecto Announces Pricing of Initial Public Offering

by Ysios Capital

Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad r...

Read more

Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline

by Ysios Capital

Funds will support preparations for potential EU conditional approval of GB0139 in IPF and multiple new Phase 2 clinical trials

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

Xavier Bosch: 'If a person has doubts ab...

by Hospital Universitari de Bellvitge

​A single virus has been able to spread all around the world in a fe...

Photos Stream